BioMed X, an independent research institute, has initiated its eighth joint research program with Merck KGaA, Darmstadt, Germany. The new program will explore the role of extrachromosomal DNA in cancer and will complement the research of two ongoing oncology programs at BioMed X in the fields of DNA damage response and RNA splicing.   Extrachromosomal circular DNA (ecDNA) was recently found to be particularly abundant in multiple human cancer cells, although its frequency varies among different ...